Evidence map›Paper›PMID 41852722›Full record

ArticleiScience2026

CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.

Romain-David Seban, Constance Lamy, Luc Cabel, Hugo Roux, Ines Dias Da Silva, Lounes Djerroudi, Doriane Gorret, Ana Inès Lalanne, Delphine Louis, Maud Milder and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Romain-David SebanDepartment of Nuclear Medicine and Endocrine Oncology, Institut Curie, Paris, France.
Constance LamyDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Luc CabelDepartment of Medical Oncology, Paris and Saint-Cloud Institut Curie, Paris, France.
Hugo RouxINSERM U932, PSL University, Institut Curie, 75005 Paris, France.
Ines Dias Da SilvaClinical Immunology Laboratory, Institut Curie, Paris, France.
Lounes DjerroudiData Department, Institut Curie, Paris, France.
Doriane GorretClinical Immunology Laboratory, Institut Curie, Paris, France.
Ana Inès LalanneClinical Immunology Laboratory, Institut Curie, Paris, France.
Delphine LouisClinical Immunology Laboratory, Institut Curie, Paris, France.
Maud MilderData Department, Institut Curie, Paris, France.
Fabien ReyalPSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France.
Enora LaasService of Breast and Gynecologic Surgery, Institut Curie, Paris, France.
Claire BonneauInstitut Curie - Saint Cloud, Surgical Oncology Department, 35, rue Dailly, 92210 Saint-Cloud, France.
Nicolas PougetService of Breast and Gynecologic Surgery, Institut Curie, Paris, France.
Marie-Paule SablinDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Jean-Yves PiergaDepartment of Medical Oncology, Paris and Saint-Cloud Institut Curie, Paris, France.
Celia DupainDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Frédérique BergerBiometry Unit, Institut Curie, PSL University, Saint-Cloud, Paris, France.
Irène BuvatInstitut Curie, Université PSL, Inserm, U1288 LITO, Orsay, France.
François-Clément BidardDepartment of Medical Oncology, Paris and Saint-Cloud Institut Curie, Paris, France.
Anne Vincent-SalomonDepartment of Pathology, Institut Curie, Paris-Sciences-Lettres Research University, Paris, France.
Christophe Le TourneauDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Cécile AlanioClinical Immunology Laboratory, Institut Curie, Paris, France.
Olivier LantzINSERM U932, PSL University, Institut Curie, 75005 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus (CMV) infection modifies immune fitness and T cell subset distribution in healthy donors. We analyzed a recent prospective cohort of 240 patients bearing triple-negative breast cancer for CMV serology status and T cell subsets and assessed recurrence-free survival (RFS) and overall survival (OS). CMV seropositivity was significantly associated with worse RFS (HR = 2.6, 95%CI = 1.2-5.7) and OS (HR = 3.0, 95%CI = 1.2-7.4) in multivariable analyses. A prognostic model incorporating CMV status alongside tumor and nodal stage improved risk stratification. The impact of CMV status was not confirmed in another less well characterized, more ancient cohort (

Indexed as

Cell biologyOncologyPathology

Identifiers

PMID41852722
PMCPMC12992515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.